Cormorant Asset Management sold 50,000 shares of Praxis Precision Medicines (PRAX) in Q4 2025 for $9.31 million, but the position still increased by $227 million in value due to stock appreciation. PRAX remains Cormorant's largest holding at $280 million. The biotech stock has surged 700% over the past year and is advancing multiple late-stage therapies for neurological disorders with strong cash reserves of $926 million.

EyePoint, Inc. (Nasdaq: EYPT) granted non-statutory stock options to purchase 20,000 shares of common stock to six new employees as inducement awards on March 13, 2026, with an exercise price of $13.20 per share. The options vest over four years with a ten-year term. The company continues advancing its lead product DURAVYU in Phase 3 trials for wet AMD and DME, with topline data expected beginning in mid-2026 for wet AMD.

Parkman Healthcare Partners established a new $20 million position in EyePoint Pharmaceuticals by purchasing 1.088 million shares in Q4 2025. EyePoint shares have surged 93% over the past year as the company advances DURAVYU, a sustained-release therapy for retinal diseases, with Phase 3 trial data expected mid-2026. Despite significant losses and development-stage operations, the company has sufficient cash runway into late 2027.

EyePoint, Inc. (Nasdaq: EYPT) announced it will host a conference call on March 4, 2026 to report fourth quarter and full-year 2025 financial results. The clinical-stage biopharmaceutical company is advancing its lead product DURAVYU™, a sustained delivery treatment for retinal diseases, with Phase 3 pivotal trials for wet age-related macular degeneration expected to yield topline data beginning mid-2026, and first patient dosing in diabetic macular edema trials expected in Q1 2026.

EyePoint announced the appointment of Michael Campbell as Chief Commercial Officer, bringing over 30 years of ophthalmology commercial leadership experience. Campbell previously led successful launches of major retinal disease products including Lucentis and Xiidra. He will oversee commercial strategy for DURAVYU, the company's Phase 3 investigational sustained-release treatment for wet AMD and DME, with topline data expected mid-2026.

EyePoint, Inc. granted non-statutory stock options to three new employees for up to 13,900 shares at an exercise price of $15.84 per share on January 15, 2026. The options vest over four years with a ten-year term. The company continues advancing its lead product DURAVYU in Phase 3 trials for wet AMD and DME, with data expected beginning mid-2026.

EyePoint announced progress on its lead product DURAVYU (vorolanib intravitreal insert) with Phase 3 wet AMD trials on track for data readout beginning mid-2026 and Phase 3 DME program first patient dosing expected in Q1 2026. The company completed enrollment of over 900 patients across wet AMD trials in 7 months and has approximately $300 million in cash runway into Q4 2027.

EyePoint received a positive recommendation from its Data Safety Monitoring Committee for ongoing Phase 3 trials of DURAVYU, a potential treatment for wet age-related macular degeneration. The trials remain on track, with topline data expected in mid-2026.

EyePoint Pharmaceuticals reported Q3 2025 financial results, highlighting progress on DURAVYU clinical trials for wet AMD and diabetic macular edema, completed an oversubscribed $172.5 million equity financing, and positioned for key data readouts in mid-2026.

EyePoint Pharmaceuticals plans to raise approximately $150 million through a public offering of 11 million common stock shares and pre-funded warrants, with proceeds intended to advance clinical development of DURAVYU for retinal diseases.

EyePoint Pharmaceuticals will participate in multiple healthcare investment conferences in September 2025, presenting its lead product DURAVYU, an investigational sustained delivery treatment for retinal diseases.

EyePoint Pharmaceuticals will host a conference call on August 6, 2025 to discuss Q2 financial results and highlight corporate developments, focusing on their lead product DURAVYU, an investigational sustained delivery treatment for retinal diseases.